Group 1 - The core viewpoint of the articles highlights the mixed performance of the U.S. stock market, with the Nasdaq and S&P 500 reaching new closing highs, while the Dow remained flat [1] - The Nasdaq Biotechnology Index saw a rise of 0.89%, with several component stocks experiencing significant gains, such as KYTX up over 32% and NTLA up over 19% [2][3] - The Nasdaq Biotechnology ETF (513290) experienced a substantial increase of 6.22%, with strong net inflows for 16 consecutive days [1][2] Group 2 - The Federal Reserve's recent meeting minutes indicate that more than half of the participating officials expect at least two more rate cuts this year, while some anticipate only one or no cuts in 2025 [4][5] - Pfizer announced a voluntary price reduction of up to 85% on many of its foundational and specialty drugs, which has positively impacted its stock price and those of other pharmaceutical companies [5] - The Nasdaq Biotechnology Index (NBI) serves as a key indicator for global innovative pharmaceuticals, combining top U.S. biotech leaders and international innovators, with the top ten weighted stocks accounting for nearly 50% of the index [6][7] Group 3 - The Nasdaq Biotechnology ETF (513290) is the only ETF that focuses on global innovative pharmaceuticals, with a low entry point of around 100 yuan, making it accessible for investors [7] - The minimum subscription unit for the Nasdaq Biotechnology ETF has been reduced from 1 million to 500,000 units, lowering the barrier for entry for larger investors [7]